Divya Chari
About Divya Chari
Divya Chari serves as the Head of Clinical Operations at Structure Therapeutics, bringing over 18 years of experience in global clinical trials, particularly in oncology. She has held various roles in clinical operations across several companies, including Pharmacyclics and KaloBios, and has a strong educational background in Management Information Systems and Biochemistry.
Work at Structure Therapeutics
Divya Chari serves as the Head of Clinical Operations at Structure Therapeutics, a position she has held since 2023. In this role, she oversees the clinical operations team, ensuring the effective management of clinical trials. Based in the San Francisco Bay Area, she focuses on delivering high-quality results in the development of new therapies. Her leadership is instrumental in advancing the company's clinical programs.
Previous Experience in Clinical Operations
Before joining Structure Therapeutics, Divya Chari held several key positions in clinical operations. She worked as an Associate Director at Pharmacyclics from 2014 to 2020, where she contributed to various clinical projects. Prior to that, she was a Clinical Program Manager at KaloBios for one year. Her career began as a Clinical Research Associate at ProTrials Research from 2005 to 2008, followed by a five-year tenure as Manager of Clinical Operations at Affymax.
Education and Expertise
Divya Chari holds a Bachelor of Science (B.S.) in Biochemistry from the University of Mysore and a degree in Management Information Systems from the University of San Francisco. Her educational background supports her extensive experience in clinical operations, particularly in managing global clinical trials. She has over 18 years of experience, specializing in Phase 1-IV clinical trials with a focus on oncology.
Clinical Trials and Regulatory Expertise
Divya Chari has a proven track record in supporting successful New Drug Applications (NDAs) across various therapeutic areas. She is skilled in managing studies from Investigational New Drug (IND) applications to NDAs, overseeing multiple global Phase I to III programs. Her expertise includes building and leading high-performance teams, which is crucial for the successful execution of clinical trials.